BIOS Capital Management LP Buys Shares of 1,207,709 Lantern Pharma Inc. (NASDAQ:LTRN)

BIOS Capital Management LP bought a new stake in shares of Lantern Pharma Inc. (NASDAQ:LTRNFree Report) during the 4th quarter, HoldingsChannel reports. The firm bought 1,207,709 shares of the company’s stock, valued at approximately $3,853,000. Lantern Pharma accounts for about 4.1% of BIOS Capital Management LP’s portfolio, making the stock its 4th biggest position. BIOS Capital Management LP owned 0.11% of Lantern Pharma as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new stake in Lantern Pharma during the 4th quarter valued at $32,000. Westside Investment Management Inc. boosted its stake in Lantern Pharma by 166.5% during the 3rd quarter. Westside Investment Management Inc. now owns 30,650 shares of the company’s stock valued at $112,000 after purchasing an additional 19,150 shares during the last quarter. Finally, CM Management LLC boosted its stake in Lantern Pharma by 8.1% during the 4th quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $638,000 after purchasing an additional 15,000 shares during the last quarter. 28.62% of the stock is currently owned by hedge funds and other institutional investors.

Lantern Pharma Trading Up 1.6 %

Shares of LTRN opened at $3.80 on Monday. The business’s fifty day simple moving average is $4.27 and its two-hundred day simple moving average is $3.78. Lantern Pharma Inc. has a 12 month low of $2.79 and a 12 month high of $11.99. The company has a market cap of $40.98 million, a price-to-earnings ratio of -2.13 and a beta of 1.64.

About Lantern Pharma

(Free Report)

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.

See Also

Want to see what other hedge funds are holding LTRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantern Pharma Inc. (NASDAQ:LTRNFree Report).

Institutional Ownership by Quarter for Lantern Pharma (NASDAQ:LTRN)

Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.